Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma.
Tashiro T, Imamura K, Tomita Y, Tamanoi D, Takaki A, Sugahara K, Sato R, Saruwatari K, Sakata S, Inaba M, Ushijima S, Hirata N, Sakagami T. Tashiro T, et al. Among authors: inaba m. Int J Mol Sci. 2020 Dec 19;21(24):9705. doi: 10.3390/ijms21249705. Int J Mol Sci. 2020. PMID: 33352665 Free PMC article.
[A case of lymphomatoid granulomatosis].
Inaba M, Hirata N, Ushijima S, Saisyoji T, Kitaoka M, Yoshinaga T. Inaba M, et al. Nihon Kokyuki Gakkai Zasshi. 2009 Oct;47(10):937-42. Nihon Kokyuki Gakkai Zasshi. 2009. PMID: 19882919 Japanese.
[A case of bronchial glomus tumor].
Inaba M, Ushijima S, Hirata N, Saisyoji T, Kitaoka M, Yoshinaga T. Inaba M, et al. Nihon Kokyuki Gakkai Zasshi. 2010 Apr;48(4):303-6. Nihon Kokyuki Gakkai Zasshi. 2010. PMID: 20432972 Japanese.
Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C, Sasaki JI, Saeki S, Iwamoto N, Inaba M, Ushijima S, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Hayashi M, Kai Y, Saito H, Isobe T, Kohrogi H, Hamada A. Endo-Tsukude C, et al. Among authors: inaba m. Biol Pharm Bull. 2018;41(1):47-56. doi: 10.1248/bpb.b17-00521. Biol Pharm Bull. 2018. PMID: 29311482 Free article.
Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S, Ichiyasu H, Ikeda T, Inaba M, Kashiwabara K, Sadamatsu T, Sato N, Akaike K, Okabayashi H, Saruwatari K, Tomita Y, Saeki S, Hirata N, Yoshinaga T, Fujii K. Hamada S, et al. Among authors: inaba m. BMC Pulm Med. 2019 Apr 2;19(1):72. doi: 10.1186/s12890-019-0838-2. BMC Pulm Med. 2019. PMID: 30940113 Free PMC article.
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Jodai T, Saruwatari K, Ikeda T, Moriyama E, Kashiwabara K, Shingu N, Iyonaga K, Inaba M, Ajishi Y, Honda C, Hirosako S, Maruyama H, Kakiuchi Y, Eida H, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Jodai T, et al. Among authors: inaba m. Int J Clin Oncol. 2021 Jan;26(1):78-86. doi: 10.1007/s10147-020-01789-5. Epub 2020 Sep 23. Int J Clin Oncol. 2021. PMID: 32965577
1,558 results